Quick View
| Metric | Current Period | Same Period Previous Year | YoY |
|---|---|---|---|
| Revenue | ¥2636.3B | ¥2306.5B | +14.3% |
| Operating Income | - | - | - |
| Profit Before Tax | ¥374.6B | ¥219.8B | +70.5% |
| Net Income | ¥306.2B | ¥163.2B | +87.6% |
| ROE | 3.3% | 1.8% | - |
Executive Summary
The current period results showed increases in both revenue and profit, with particularly strong growth in net income. Revenue was ¥2,636.3B (¥2,306.5B in the previous year, YoY +14.3%), profit before tax was ¥374.6B (¥219.8B, YoY +70.5%), and net income was ¥306.2B (¥163.2B, YoY +87.6%). The fact that net income growth exceeded profit-before-tax growth was attributable to the decline in the effective tax rate from 25.7% to 18.3%. The gross profit margin improved to 74.8% (73.2% in the previous year), while the SG&A ratio improved to 32.2% (34.5%), indicating that expenses remained restrained relative to top-line growth.
Factors Affecting Performance
【Revenue】Revenue was ¥2,636.3B, representing a YoY increase of +14.3%. As segment-level details are not included in the disclosed data, the analysis is limited to a company-wide basis.
【Profit and Loss】Gross profit was ¥1,972.8B (gross profit margin of 74.8%, +1.6pt from 73.2% in the previous year), SG&A expenses were ¥848.1B (SG&A ratio of 32.2%, improved from 34.5% in the previous year), and R&D expenses were ¥463.2B (an absolute decrease of -11.8% from ¥525.0B in the previous year; 17.6% of revenue versus 22.8% in the previous year), indicating that expenses were relatively restrained amid revenue growth. Other expenses increased significantly to ¥291.4B (¥128.8B in the previous year, +126.4%), which restrained the growth rate of profit before tax. Meanwhile, net financial income turned positive at +¥49.9B (net -¥7.3B in the previous year), as financial income of ¥67.3B exceeded financial expenses of ¥17.4B. Profit before tax was ¥374.6B (+70.5%), income taxes were ¥68.5B, and the effective tax rate declined to 18.3% (25.7% in the previous year), resulting in net income of ¥306.2B (+87.6%). Improvements in the gross profit margin and SG&A ratio, combined with the decline in the effective tax rate, resulted in higher revenue and profit.
Key Financial Indicators
【Profitability】The gross profit margin was 74.8% (73.2% in the previous year), the SG&A ratio was 32.2% (34.5%), and the R&D expense ratio was 17.6% (22.8%; absolute amount down -11.8% YoY), all indicating improvement. The net profit margin was 11.6%, improving by 4.5pt from 7.1% in the previous year, supported by greater efficiency in the expense structure and a lower tax burden.【Cash Flow Quality】Operating Cash Flow (OCF) was ¥813.3B, reaching 2.66 times net income of ¥306.2B, indicating a favorable level of earnings cash conversion.【Investment Efficiency】ROE was 3.3% (3.34% based on period-end equity, equivalent to 1.83% in the previous year), improving from the previous year; however, as this is a six-month result, the annualized figure may differ.【Financial Soundness】The equity ratio was 81.0% (80.6% in the previous year), maintaining a nearly unchanged high level, while cash and deposits accumulated to ¥2,650.8B. Interest-bearing financial liabilities totaled ¥272.1B on a combined current and non-current basis, a limited amount, indicating a conservative capital structure.
Cash Flow Analysis
Operating Cash Flow was ¥813.3B, a substantial YoY increase of +104.2% from ¥398.4B in the previous year, reaching 2.66 times net income of ¥306.2B. Contributing factors included a ¥329.6B decrease in trade receivables, a ¥34.4B decrease in inventories, a ¥33.2B increase in trade payables, and a ¥103.5B increase in provisions, partly offset by a ¥100.2B decrease in contract liabilities. Payments of income taxes increased to ¥54.1B (¥4.8B in the previous year), but the greater improvement in working capital boosted OCF. Investing Cash Flow was -¥175.6B (-¥347.4B in the previous year), primarily comprising capital expenditures of ¥185.5B and acquisitions of intangible assets of ¥35.3B (down from ¥101.2B in the previous year). Financing Cash Flow was -¥187.6B (-¥172.2B in the previous year), mainly due to dividend payments of ¥167.5B, while share repurchases were negligible at ¥0.1B. As a result, free cash flow was ¥637.8B, a level more than sufficient to cover dividends and capital expenditures. Cash and cash equivalents increased to ¥2,650.8B at period-end (¥2,187.7B in the previous year), providing substantial financial flexibility.
Earnings Quality
The improvement in profitability during the current period reflects a combination of recurring factors, namely improvements in the gross profit margin and SG&A ratio, and a factor with a non-recurring element, namely the decline in the effective tax rate. The effective tax rate declined from 25.7% to 18.3%, resulting in net income growth (+87.6%) exceeding profit-before-tax growth (+70.5%). Whether this decline in the tax rate is sustainable or attributable to temporary factors will be an area of focus when evaluating the sustainability of net income growth. In addition, other expenses expanded to ¥291.4B (¥128.8B in the previous year), restraining profit-before-tax growth, and their composition and nature require further assessment. Comprehensive income was ¥394.3B, exceeding net income of ¥306.2B by ¥88.2B, reversing the relationship seen in the previous year, when comprehensive income of ¥62.3B was below net income of ¥163.2B. This difference was primarily attributable to an improvement in foreign currency translation adjustments (from -¥95.2B in the previous year to +¥84.6B in the current period), indicating that the yen translation of overseas assets and liabilities contributed positively. The fact that OCF reached 2.66 times net income suggests that current-period earnings were of high quality and accompanied by cash generation.
Earnings Forecast and Guidance
Progress against the full-year outlook was 50.7% for revenue of ¥2,636.3B against the forecast of ¥5,200.0B, and 40.8% for net income of ¥306.2B against the forecast of ¥750.0B. While revenue was broadly in line with the standard first-half progress level of 50%, net income was somewhat behind schedule, making profit accumulation in the second half a prerequisite for achieving the plan. Whether the lag in net income progress will be eliminated depends on trends in the full-year effective tax rate and non-operating expenses. In the current results, both the earnings forecast and dividend forecast were reported as “No” revisions.
Shareholder Returns
An interim dividend of ¥35 per share was paid. The full-year dividend forecast is ¥70, and the full-year forecast EPS is ¥143.27, implying a payout ratio of 48.9%. Share repurchases were negligible at ¥0.1B, and shareholder returns during the current period were centered on dividends. Dividend payments of ¥167.5B were well below free cash flow of ¥637.8B, indicating that the current dividend level is within the range supported by cash flow.
Risk Factors
-
Increase in non-operating expenses: Other expenses increased to ¥291.4B, up +126.4% from ¥128.8B in the previous year, and restrained profit-before-tax growth (+70.5%) relative to net income growth (+87.6%). The future appearance of profit margins will depend on whether these expenses are temporary or recurring in nature.
-
Effective tax rate fluctuations: The effective tax rate declined from 25.7% to 18.3%, contributing to the increase in net income. Whether this level can be maintained throughout the full year will affect the achievement of the full-year net income progress target (40.8%).
-
Level of goodwill and intangible assets: Goodwill was ¥1,817.2B, equivalent to 19.8% of net assets, while total intangible assets were ¥1,956.3B, equivalent to 17.3% of total assets. Assets arising from M&A account for a certain proportion of the balance sheet, making it meaningful to monitor progress against the earnings plans underlying their valuation.
Industry Benchmark (Reference; Company Analysis)
Industry Benchmark (pharma)
Profitability and Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Net Profit Margin | 11.6% | – | – |
Due to limited comparison data, the company’s relative position within the industry should be regarded as reference information only.
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 14.3% | – | – |
Due to limited comparison data, the company’s relative position within the industry should be regarded as reference information only.
Source: Company compilation
Key Points in the Results
-
Net income growth (+87.6%) exceeded profit-before-tax growth (+70.5%), with the difference attributable to the decline in the effective tax rate (25.7%→18.3%). The sustainability of this tax rate will be an important point to verify when assessing the quality of future earnings growth.
-
Operating Cash Flow reached 2.66 times net income, and free cash flow was ample at ¥637.8B. Cash generation exceeding dividends and capital expenditures supports the company’s financial flexibility.
-
Progress against the full-year earnings forecast was somewhat behind for net income at 40.8%, compared with 50.7% for revenue, indicating that profit accumulation in the second half is a prerequisite for achieving the plan.
Theoretical Share Price (Reference Value)
This is a mechanically calculated reference range based solely on publicly disclosed data using a residual income model (Ohlson-type model with an explicit five-year fade). It is not a forecast of the market share price or a recommendation of any specific investment action.
| Scenario | Theoretical Share Price |
|---|---|
| bear | ¥1,667 |
| base | ¥1,736 |
| bull | ¥1,769 |
| Calculation Assumption | Value |
|---|---|
| Book Value Per Share (BPS) | ¥1,750 |
| Adjusted Forecast EPS | ¥155.4 |
| Cost of Equity r | 9.15% (10-year government bond 2.65% + equity risk premium 6.00% + size premium 0.50%) |
| Residual Income Persistence Coefficient ω / Explicit Forecast Period | 0.62 / 5 years |
| Assumed Payout Ratio | 48.9% |
| Forecast EPS Confidence Adjustment | ×1.085 (based on the industry’s historical guidance achievement rate) |
| Implied PBR / PER | 0.99x / 11.2x |
Sensitivity: ¥1,689–¥1,786 at cost of equity ±1%, and ¥1,736–¥1,737 at ω±0.1.
Notes:
- As forecast ROE is below the cost of equity, the theoretical value is below book value per share.
- Net assets as of the quarter-end are used (there is a timing difference from the full-year forecast).
(Calculation model: Residual Income Model / Interest Rate Reference Month: 2026-06 / This value does not predict or guarantee the future share price.)
This report is an earnings analysis document automatically generated by AI through analysis of XBRL earnings report data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, and you should consult a professional as necessary.
---End of Report---
AI Financial Analysis
Executive Summary
FY2026 Q2 was a strong operating and cash-generation period for Kyowa Kirin, with revenue growth, margin expansion and sharply higher net income. Revenue increased 14.3% YoY to ¥263.6bn. Gross profit rose to ¥197.3bn, producing a gross margin of 74.8%, up 165bp from 73.2% a year earlier. SG&A expense increased 6.7% to ¥84.8bn, materially slower than revenue growth. This created favorable operating leverage and lifted operating income 25.9% to ¥112.5bn. The operating margin expanded 393bp to 42.7% from 38.7%. R&D spending was ¥46.3bn, equivalent to a substantial 17.6% of revenue and within the normal 15-20% range for an innovator pharmaceutical company. Profit before tax increased 70.5% to ¥37.5bn, while net income rose 87.6% to ¥30.6bn. The gap between operating income and profit before tax was, however, substantial, principally reflecting ¥29.1bn of other expenses, including ¥5.6bn of impairment losses. The resulting net margin improved to 11.6% from 7.1% in the prior-year period, an expansion of 453bp. Operating cash flow was particularly strong at ¥81.3bn, 2.66x net income, and free cash flow reached ¥63.8bn. Cash conversion benefited from a ¥33.0bn reduction in trade receivables, although inventory increased by ¥3.4bn and inventory days remain elevated. The balance sheet remains exceptionally resilient, with an 81.0% equity ratio, ¥265.1bn of cash and equivalents, and a current ratio of 2.84x. The interim dividend was raised to ¥35 per share from ¥30, while the unchanged full-year dividend forecast of ¥70 implies a ¥35 year-end dividend. Full-year revenue guidance of ¥520.0bn has been 50.7% achieved at Q2, slightly ahead of normal seasonality, while net-income guidance of ¥75.0bn has been 40.8% achieved. The earnings outlook therefore depends on a materially stronger second half, but the unchanged guidance indicates management views the current performance as consistent with its full-year plan.
Profitability Analysis
The annualized DuPont ROE is 6.7%, decomposed into an 11.6% net profit margin, 0.466x asset turnover and 1.23x financial leverage. The main constraint on ROE is low asset turnover rather than leverage: the company deliberately operates with a very equity-rich capital structure, so financial leverage contributes little incremental return. The Q2 margin trajectory was favorable, with gross margin rising 165bp and operating margin rising 393bp YoY. Revenue growth of 14.3% exceeded SG&A growth of 6.7%, reducing the SG&A-to-revenue ratio by 228bp to 32.2% and demonstrating positive operating leverage. R&D expense of ¥46.3bn, or 17.6% of revenue, supports pipeline renewal while remaining consistent with industry-standard innovator-pharma investment intensity. Operating profit expansion was therefore driven by both sales growth and disciplined overhead absorption. Net-income growth outpaced operating-income growth because profit before tax rose 70.5%, although the absolute bridge from operating income to pre-tax income remains weak due to ¥29.1bn in other expenses. The reported 0.333 interest-burden ratio is a quality-alert concern because it indicates that only one-third of EBIT translated into pre-tax profit under the supplied extended DuPont calculation. However, actual finance costs were only ¥1.7bn and were more than offset by ¥6.7bn of finance income; the low interest-burden result is principally associated with below-operating-income expense items rather than debt-service pressure. This distinction matters because the balance sheet itself does not indicate aggressive debt financing. The effective tax rate was 18.3%, with a tax burden of 0.817, supporting conversion of pre-tax earnings to net income. Annualized ROE remains below the 8% threshold generally associated with a stronger return profile, despite excellent operating margins, because the capital base is large relative to sales and earnings.
Growth Assessment
Top-line momentum is healthy, with Q2 cumulative revenue up 14.3% YoY to ¥263.6bn and already representing 50.7% of full-year guidance. The revenue progress rate is 0.7 percentage points above the standard 50% Q2 run rate, indicating that the sales target is broadly on track. Gross profit grew 16.9%, faster than revenue, confirming favorable product mix, pricing and/or production-cost absorption. Operating income increased 25.9%, materially outperforming sales due to operating leverage. Net income increased 87.6%, but this growth rate should not be extrapolated mechanically because the period includes a large movement in below-operating-income expenses and impairment losses. The full-year net-income target of ¥75.0bn is only 40.8% achieved at Q2, 9.2 percentage points below the standard progress rate but not beyond the 10-point deviation threshold. Meeting the forecast requires second-half net income of approximately ¥44.4bn, versus ¥30.6bn in the first half. The unchanged forecast suggests management expects improved second-half earnings conversion or seasonally stronger contributions. The pharmaceutical growth profile is underpinned by R&D intensity of 17.6%, which is consistent with maintaining a clinically relevant development pipeline. Sustainability of growth should be assessed against the ability to retain the current gross-margin gains while controlling commercial and development expenditure. The absence of a forecast revision despite above-plan revenue progress indicates that management remains appropriately cautious about second-half costs, product mix and non-operating items.
Financial Health
Financial health is very strong. Total equity was ¥916.2bn against total liabilities of ¥214.8bn, resulting in an equity ratio of 81.0%. Debt-to-equity was a conservative 0.23x, well below the 1.0x level generally associated with conservative balance-sheet risk. Current assets of ¥517.8bn exceeded estimated current liabilities of ¥182.4bn by approximately ¥335.4bn, equivalent to a current ratio of 2.84x. The quick ratio was also strong at approximately 2.49x, based on cash, receivables and other current liquid assets relative to current liabilities. Accordingly, there is no current-ratio warning and no apparent short-term maturity mismatch. Cash and cash equivalents increased to ¥265.1bn and provide substantial flexibility for R&D, business development, capex and shareholder distributions. Accounts payable of ¥125.3bn are adequately covered by cash and receivables alone. Goodwill was ¥181.7bn, or 19.8% of equity and 16.1% of assets, which is within the healthy benchmark of below 30% of equity. Intangible assets were ¥195.6bn, or 17.3% of assets, also below the 20% balance-sheet concentration benchmark. The company is therefore not overly dependent on the carrying value of acquired goodwill and intangible assets, although the ¥5.6bn impairment charge shows that acquired or capitalized asset values require ongoing monitoring. Off-balance-sheet-like recurring commitments evidenced in cash flow include lease payments of ¥2.0bn during the period, which are modest relative to operating cash flow.
Notable B/S Changes
Accounts receivable: -¥27.9bn (-15.4%) YoY to ¥153.3bn - major source of operating-cash-flow improvement, although DSO remains elevated at 106 days. Cash and cash equivalents: +¥46.3bn (+21.2%) YoY to ¥265.1bn - strengthened liquidity following robust operating cash generation. Other current liabilities: -¥11.5bn (-34.2%) YoY to ¥22.1bn - reduced short-term obligations and further improved liquidity. Total equity: +¥22.8bn (+2.6%) YoY to ¥916.2bn - retained profitability and positive OCI supported an already strong capital base. Property, plant and equipment: +¥4.7bn (+3.3%) YoY to ¥145.9bn - continued investment in production and operating infrastructure. Goodwill: -¥1.8bn (-1.0%) YoY to ¥181.7bn; intangible assets: -¥5.8bn (-2.9%) YoY to ¥195.6bn - modest reduction in acquired-asset balances, while the ¥5.6bn impairment loss warrants continued recoverability monitoring.
Cash Flow Quality
Cash-flow quality was high in Q2. Operating cash flow of ¥81.3bn was 2.66x reported net income of ¥30.6bn, far above the 0.8x level that would signal weak cash conversion. Free cash flow was ¥63.8bn after ¥18.6bn of capital expenditures. The accruals ratio was negative 4.5%, which is consistent with cash realization exceeding accounting earnings and supports the quality of reported profit. The principal cash-flow contributor was a ¥33.0bn reduction in trade receivables, which materially boosted operating cash flow. This is favorable in the current period, but the high receivable-days alert of 106 days remains material: collections and revenue cut-off should remain a monitoring focus because DSO remains well above the 60-day benchmark. Inventory increased by ¥3.4bn, and inventory days of 178 are materially above both 60-day and 90-day warning thresholds. For a pharmaceutical company, inventories can reflect supply assurance, launch preparation and manufacturing lead times, but the level increases working-capital and obsolescence risk if demand, reimbursement or product mix changes. Cash flow also benefited from a ¥3.3bn increase in payables and a ¥10.4bn increase in provisions, while contract liabilities decreased by ¥10.0bn. These movements do not negate the strong cash result, but they reinforce the need to track whether receivable collection and inventory control persist through the second half. Investing outflow of ¥17.6bn was predominantly funded by internally generated cash, and financing outflow of ¥18.8bn was mainly dividends. Net cash increased ¥46.3bn during the half.
Dividend Sustainability
The Q2 dividend was ¥35 per share, up from ¥30 per share in the prior-year period. The full-year dividend forecast remains ¥70 per share, implying a ¥35 year-end payment and no change to the stated annual shareholder-distribution plan. The interim payout ratio was 60.1% of first-half EPS, marginally above the conventional 60% sustainability reference point. This interim ratio should be viewed alongside full-year guidance: ¥70 per share represents an implied full-year dividend payout ratio of approximately 48.9% based on forecast EPS of ¥143.27. Free cash flow of ¥63.8bn covered dividends paid of ¥16.8bn by 3.47x. Capital expenditure of ¥18.6bn, dividends and the de minimis ¥0.006bn share repurchase were all covered by operating cash flow. The total return ratio is effectively aligned with the dividend payout ratio because buybacks were immaterial. Strong liquidity, low leverage and substantial FCF coverage support the current dividend level. The key determinant of distribution capacity is not balance-sheet funding but delivery of the full-year earnings forecast and maintenance of working-capital discipline.
Risk Assessment
Business risks include Inventory risk is elevated: inventory days of 178 materially exceed pharmaceutical and general working-capital benchmarks. Slow-moving inventory, product-expiry exposure, demand volatility or manufacturing-buffer requirements could lead to write-downs and lower future cash conversion., Receivable collection risk remains elevated, with DSO of 106 days versus a 60-day benchmark. Although receivables declined by ¥33.0bn in the period, sustained collection performance is necessary to validate the operating-cash-flow strength., Pharmaceutical development, regulatory and commercialization risk remains inherent. R&D spending of ¥46.3bn, or 17.6% of sales, is strategically appropriate but requires successful pipeline progression and commercial execution to earn an adequate return., The ¥5.6bn impairment loss highlights risk around the recoverability of acquired or intangible asset values. Future clinical, regulatory, market-access or product-performance setbacks could trigger further impairment..
Financial risks include The extended DuPont interest-burden ratio of 0.333 is weak and is flagged because the bridge from EBIT to pre-tax income is unusually large. The direct financing-risk interpretation is moderated by finance income exceeding finance costs and by D/E of only 0.23x, but below-operating-income charges remain a material earnings-conversion risk., Profit before tax was only ¥37.5bn versus operating income of ¥112.5bn, reflecting ¥29.1bn of other expenses. This reduces predictability of conversion from operating performance to shareholder earnings., Goodwill and intangible assets together total ¥377.4bn, or 33.4% of total assets. Individually their ratios remain within benchmark ranges, but these assets remain exposed to impairment if expected cash flows weaken., Full-year net-income guidance requires approximately ¥44.4bn in second-half profit, above first-half net income of ¥30.6bn. Execution risk is therefore greater for net income than for revenue..
Key concerns include Highest priority: high inventory days and high receivable days combine to create a working-capital risk despite the current period's excellent operating cash flow., High priority: the large gap between operating income and pre-tax income should be monitored for recurrence, especially other expenses and impairment charges., Moderate priority: maintenance of gross-margin expansion and SG&A discipline is important because current earnings momentum relies on favorable operating leverage., Moderate priority: pharma-specific risks include clinical-trial outcomes, patent and competitive dynamics, regulatory approvals, reimbursement/pricing pressure and product-supply quality..
Investment Implications
Key takeaways include Revenue growth of 14.3%, gross-margin expansion of 165bp and operating-margin expansion of 393bp demonstrate strong underlying operating momentum., Operating cash flow of ¥81.3bn and free cash flow of ¥63.8bn provide strong validation of earnings quality in the period., An 81.0% equity ratio, 2.84x current ratio and 0.23x D/E indicate substantial financial resilience and capital-allocation flexibility., The central analytical tension is that excellent operating profit conversion to cash coexists with weak EBIT-to-pre-tax-profit conversion due to substantial other expenses and impairment., Unchanged guidance leaves second-half earnings delivery, receivable collection and inventory normalization as the principal indicators of whether Q2 strength can be sustained..
Metrics to watch include Second-half net income versus the approximately ¥44.4bn required to achieve ¥75.0bn full-year guidance, Other expenses and impairment losses relative to operating income, DSO from the current 106 days and the durability of the receivables cash inflow, DIO from the current 178 days, inventory write-downs and product-supply requirements, Gross margin, SG&A-to-sales ratio and R&D intensity, Goodwill and intangible-asset impairment indicators, Free cash flow coverage of the ¥70 per share annual dividend.
Regarding relative positioning, Kyowa Kirin displays a high-quality profitability and balance-sheet profile for an innovator pharmaceutical company: 74.8% gross margin, 42.7% operating margin, 17.6% R&D intensity, strong FCF generation and low leverage. Its relative constraints are modest annualized ROE of 6.7%, capital intensity from a large equity base, elevated receivable and inventory days, and a sizeable recurring-risk gap between operating income and pre-tax income.